RxDoctor Payments Data

Andrea Lorio, DO

Pulmonary Disease · Houma, LANPI 1992016133

Payments from drug & device makers

$8,873in general payments, 2019–2025

Across 134 payments — averaging $66.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • AstraZeneca$1K
  • GSK$658
  • Mylan Specialty L.p.$200
  • Boehringer Ingelheim$183
  • Sunovion Pharmaceuticals Inc.$168
  • plus $811 from 15 others

What the payments were for

  • Travel & lodging$1,28214%
  • Food & beverage$3,55240%
  • Education$4,04046%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,873 in reported general payments places this provider in the 60th percentile of 189 pulmonary disease providers in Louisiana.

See all pulmonary disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$84,688
Medicare patients
312
Services billed
947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter172$134,606
Breztri AerosphereBudesonide/Glycopyr/Formoterol107$72,652
Stiolto RespimatTiotropium Br/Olodaterol Hcl47$35,124
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr59$31,588
Zileuton ErZileuton12$16,413
Breo ElliptaFluticasone/Vilanterol28$13,175
Spiriva RespimatTiotropium Bromide17$8,544
Albuterol Sulfate HfaAlbuterol Sulfate124$2,710
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,684
Ventolin HfaAlbuterol Sulfate29$1,664
Proair RespiclickAlbuterol Sulfate12$828
Ipratropium Bromide22$656
Levocetirizine Dihydrochloride66$491
Montelukast Sodium56$475
Fluticasone Propionate27$309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$658$179,370259 claims
AstraZenecaBreztri Aerosphere$1,369$72,652107 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$183$43,66964 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 189 pulmonary disease providers in Louisiana.

Other pulmonary disease in Houma

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →